Viridia Life Sciences is a subsidiary of ATAI that investigates DMT and the possible administration of it.
Viridia Life Sciences
“This pragmatic approach to simplifying DMT administration and the in-clinic treatment paradigm will help people access not only the neurogenic benefits of DMT, but also the personal insights that can accompany psychedelic-assisted psychotherapy… The impact for patients and their families may be transformative.”
The company expects to begin human clinical trials in 2021.
One of the things that Viridia is trying to develop is a slower onset and a control of the intensity of the experience.
Key Staff
- Glenn Short, CEO
- Srinivas Eao, CSO (also of ATAI)
- Florian Brand, Co-founder, board member (CEO ATAI)
News
- Combatting resistant depression with DMT and digital therapy (Health Europe, October 2020)
- ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews (Benzinga, July 2020)
Topics of Interest
Depression
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates